MINNEAPOLIS, Minn., May 17, 2018 – A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Kite, a Gilead Company. CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. Under the terms of the agreement, CIBMTR will collect and analyze long-term safety and efficacy data for YESCARTA® in a commercial setting.
YESCARTA® is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. YESCARTA® is not indicated for the treatment of patients with primary central nervous system lymphoma.
“We are delighted to announce this partnership with Kite, a pioneer in the emerging cell therapy field,” said Mary M. Horowitz, M.D., Chief Scientific Director of CIBMTR. “This collaboration will leverage CIBMTR’s deep experience collecting and analyzing data on both the
Article originally posted at